Tumor-Infiltrating Lymphocytes and Interleukin-2: Dose and Schedules of Administration in the Treatment of Metastatic Cancer-Reference-Cited by-同舟云学术

Tumor-Infiltrating Lymphocytes and Interleukin-2: Dose and Schedules of Administration in the Treatment of Metastatic Cancer

Published:2004-12 Issue:6 Volume:19 Page:730-737
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Dillman Robert¹,Schiltz Patric¹,Priest Carol De¹,Barth Neil¹,Beutel Linda¹,Leon Cristina de¹,O'Connor Audrey¹,Nayak Shankar¹

Affiliation:

1. Hoag Cancer Center, Newport Beach, CA

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2004.19.730

Reference36 articles.

1. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

2. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

3. The Clinical Experience with Interleukin-2 in Cancer Therapy

4. What to do with IL-2?

5. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging technologies for genetic control systems in cellular therapies;Current Opinion in Biotechnology;2022-12

2. Characteristics of CD8+ and CD4+ Tissue-Resident Memory Lymphocytes in the Gastrointestinal Tract;Advanced Gut & Microbiome Research;2022-05-18

3. Impact of allogeneic stem cell manufacturing decisions on cost of goods, process robustness and reimbursement;Biochemical Engineering Journal;2018-09

4. Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer?;Theranostics;2018

5. Evolving Immunotherapy Approaches for Renal Cell Carcinoma;Current Oncology Reports;2016-07-30